News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
255,329 Results
Type
Article (13679)
Company Profile (256)
Press Release (241394)
Section
Business (79059)
Career Advice (146)
Deals (13163)
Drug Delivery (27)
Drug Development (50086)
Employer Resources (31)
FDA (5614)
Job Trends (5100)
News (143400)
Policy (10011)
Tag
Academia (900)
Africa (145)
Alabama (26)
Allergies (29)
Alliances (21370)
Alzheimer's disease (675)
Antibody-drug conjugate (ADC) (30)
Approvals (5587)
Arizona (38)
Artificial intelligence (25)
Asia (16586)
Australia (2770)
Bankruptcy (96)
Best Places to Work (4309)
Biotechnology (213)
C2C Services and Suppliers (10604)
California (989)
Canada (430)
Cancer (191)
Career advice (127)
CAR-T (30)
Cell therapy (79)
China (69)
Clinical research (38804)
Collaboration (67)
Colorado (33)
Connecticut (31)
COVID-19 (969)
Cystic fibrosis (58)
Data (89)
Diabetes (27)
Diagnostics (1147)
Earnings (28340)
Employer resources (29)
Europe (35526)
Events (45463)
Executive appointments (56)
FDA (5693)
Florida (92)
Funding (63)
Gene therapy (65)
GLP-1 (254)
Government (1050)
Healthcare (6492)
Hotbed/Location (184116)
Illinois (60)
Indiana (42)
Infectious disease (977)
Inflammatory bowel disease (75)
IPO (7115)
Job creations (856)
Job search strategy (123)
Kansas (51)
Layoffs (173)
Legal (1368)
Liver cancer (24)
Lung cancer (40)
Maryland (157)
Massachusetts (826)
Medical device (2510)
Medtech (2510)
Mergers & acquisitions (6020)
Metabolic disorders (108)
Michigan (33)
Minnesota (59)
Neuroscience (749)
New Jersey (267)
New York (314)
NextGen Class of 2024 (1973)
Non-profit (836)
North Carolina (305)
Northern California (444)
Obesity (65)
Ohio (56)
Opinion (84)
Parkinson's disease (25)
Patents (27)
Peanut (26)
Pennsylvania (237)
People (24593)
Pharmaceutical (41)
Phase I (13614)
Phase II (18042)
Phase III (11488)
Pipeline (60)
Postmarket research (841)
Preclinical (5744)
Press Release (30)
Rare diseases (89)
Real estate (1403)
Regulatory (7978)
Research institute (928)
South America (206)
Southern California (419)
Startups (1961)
Texas (79)
United States (3908)
Vaccines (115)
Washington State (141)
Weight loss (51)
Date
Last 7 days (235)
Last 30 days (1206)
Last 365 days (21519)
2024 (14048)
2023 (22414)
2022 (26822)
2021 (27807)
2020 (23358)
2019 (16227)
2018 (11738)
2017 (13746)
2016 (11840)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7428)
255,329 Results for "yumanity therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Kineta Completes Reverse Merger with Yumanity Therapeutics
Kineta, Inc., a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced the completion of its reverse merger with Yumanity Therapeutics, Inc.
December 19, 2022
·
7 min read
Deals
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV.
December 5, 2022
·
11 min read
Business
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Yumanity Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.
November 14, 2022
·
12 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
3 min read
·
Voyager Therapeutics, Inc.
Genetown
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into definitive agreements for two strategic transactions.
June 6, 2022
·
13 min read
Policy
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
Yumanity Therapeutics, Inc. announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission.
August 29, 2022
·
9 min read
Genetown
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
Yumanity Therapeutics, Inc. announced that the registration statement on Form S-4, relating to the previously announced asset sale to Janssen Pharmaceutica NV and merger with Kineta, Inc., has been declared effective by the U.S. Securities and Exchange Commission.
November 10, 2022
·
12 min read
Business
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company’s recent corporate developments.
August 4, 2022
·
11 min read
Genetown
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today provided an update on recent corporate developments.
January 11, 2022
·
7 min read
Business
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments.
May 12, 2022
·
9 min read
1 of 25,533
Next